Outlook Therapeutics said it is accelerating preparations to launch LYTENAVA in the United States before the end of calendar 2026, positioning the drug as the only FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration, or wet AMD. Management said current estimates suggest the product could exceed $500 million in annual U.S. sales by 2030. The company said its launch work includes payer outreach, commercial supply expansion, customer targeting and hiring a retina-focused commercial team, alongside efforts on pricing, reimbursement and medical affairs. It plans to apply for a permanent HCPCS code (U.S. billing and reimbursement code) by October 1, 2026 to support post-launch reimbursement. Outlook also said commercialization is continuing in Germany, Austria and the United Kingdom, with a Netherlands launch planned later in 2026 and partner Mediconsult leading regulatory and commercial work in Switzerland for an anticipated 2027 launch. For the third quarter of fiscal 2026 ended June 30, 2026, Outlook reported a net loss attributable to common stockholders of $20.3 million, or $0.15 per basic and diluted share, versus $20.2 million, or $0.55 per share, a year earlier. Adjusted net loss was $10.9 million, or $0.09 per share, compared with $15.8 million, or $0.44 per share, in the third quarter of fiscal 2025. Cash and cash equivalents stood at $11.2 million at June 30, 2026, excluding proceeds from an August 2026 public offering expected to generate about $51.1 million in net proceeds.